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PD-1/PD-L1 signaling has cell-intrinsic
functions in certain types of mouse and
human tumors, boosting cancer growth
and promoting tumorigenesis. This
suggests that immunotherapy with PD-1
blockers may produce an effect on tumor
growth that is separate from their effect
on the immune response.
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Therapeutic antibodies targeting programmed cell
death 1 (PD-1) activate tumor-specific immunity
and have shown remarkable efficacy in the treatment
of melanoma. Yet, little is known about tumor cell-
intrinsic PD-1 pathway effects. Here, we show that
murineandhumanmelanomascontainPD-1-express-
ing cancer subpopulations and demonstrate thatmel-
anoma cell-intrinsic PD-1 promotes tumorigenesis,
even in mice lacking adaptive immunity. PD-1 inhibi-
tion on melanoma cells by RNAi, blocking antibodies,
or mutagenesis of melanoma-PD-1 signaling motifs
suppresses tumor growth in immunocompetent,
immunocompromised, andPD-1-deficient tumorgraft
recipient mice. Conversely, melanoma-specific PD-1
overexpression enhances tumorigenicity, as does
engagement of melanoma-PD-1 by its ligand, PD-L1,
whereas melanoma-PD-L1 inhibition or knockout of
host-PD-L1 attenuate growth of PD-1-positive mela-
nomas.Mechanistically, themelanoma-PD-1 receptor
modulates downstream effectors of mTOR signaling.
Our results identify melanoma cell-intrinsic functions
of the PD-1:PD-L1 axis in tumor growth and suggest
that blocking melanoma-PD-1 might contribute to
the striking clinical efficacy of anti-PD-1 therapy.INTRODUCTION
Immune checkpoints are crucial regulatory pathways that main-
tain immune homeostasis by modulating the amplitude and
quality of several adaptive and innate effector mechanisms in1242 Cell 162, 1242–1256, September 10, 2015 ª2015 Elsevier Inc.favor of immunogenic tolerance (Pardoll, 2012). Using various
strategies, such as triggering functional exhaustion of tumor-
reactive cytotoxic T-lymphocytes (CTLs), cancers exploit im-
mune checkpoints to evade antitumor immunity. Programmed
cell death 1 (PD-1) is a prominent checkpoint receptor that,
upon engagement by its ligands, PD-L1 (also known as B7-H1)
or PD-L2 (also known as B7-DC), dampens T effector functions
by inhibiting signaling downstream of the T cell receptor (TCR)
(Topalian et al., 2012a). Thus, expression of PD-1 ligands, and
particularly PD-L1, in the tumor microenvironment (TME) pro-
tects cancers from immune-mediated rejection (Dong et al.,
2002; Topalian et al., 2012a). Consequently, a number of anti-
body-based therapeutics targeting the PD-1:PD-L1 axis have
entered clinical development or have been approved for mela-
noma therapy (Postow et al., 2015).
In phase I trials (Hamid et al., 2013; Herbst et al., 2014; Topa-
lian et al., 2012b; Wolchok et al., 2013), PD-1 pathway blockade
demonstrated unprecedented response rates and encouraging
toxicity profiles in patients with advanced-stage cancers of
various etiologies, including malignant melanoma. On the basis
of recent phase III data demonstrating improved overall survival
in melanoma patients receiving PD-1 inhibitors compared to
those treated with chemotherapy, the FDA approved two
anti-PD-1 antibodies, nivolumab and pembrolizumab, for the
treatment of patients with advanced melanoma who are no
longer responding to other drugs (Postow et al., 2015; Weber
et al., 2015). PD-L1 expression by cancer cells and tumor-infil-
trating lymphocytes (TILs) (Herbst et al., 2014; Topalian et al.,
2012b; Tumeh et al., 2014), the presence of type 1 T-helper
cell (Th1)-associated inflammatory mediators (Herbst et al.,
2014; Tumeh et al., 2014), increased density and proliferation
and decreased diversity in antigen specificity of CD8+ T cells
(Tumeh et al., 2014), and the frequency of tumor-associated
neo-antigens within the TME (Gubin et al., 2014; Rizvi et al.,
2015; Yadav et al., 2014) are associated with clinical response
to PD-1 pathway interference. These findings established that
optimal anti-PD-1 cancer therapeutic efficacy requires the
activation and expansion of tumor-specific T cell immunity.
However, in addition to benefiting patients afflicted with immu-
nogenic cancers, such as malignant melanoma (Hamid et al.,
2013; Herbst et al., 2014; Topalian et al., 2012b; Wolchok et al.,
2013), PD-1 pathway blockade has also yielded meaningful clin-
ical activity in patients with lesser immunogenic cancers that
have hitherto not typically responded to immunotherapy (Herbst
et al., 2014; Topalian et al., 2012b). Moreover, patients with
advanced melanoma refractory to treatment with ipilimumab, an
FDA-approved antibody targeting the immune checkpoint pro-
tein, cytotoxic T-lymphocyte antigen (CTLA)-4, showed marked
clinical response to anti-PD-1 therapy (Hamid et al., 2013; Weber
et al., 2015; Wolchok et al., 2013). While the presence of neo-
antigens and an immune-active TME are similarly associated
with favorable outcome in melanoma patients treated with either
PD-1- (Gubin et al., 2014; Rizvi et al., 2015; Yadav et al., 2014)
or CTLA-4-directed checkpoint blockade (Snyder et al., 2014),
current evidence suggests that PD-1 inhibitors produce greater
anticancer activity and fewer immune-related adverse events
than ipilimumab (Postow et al., 2015). Taken together, these ob-
servations raise the possibility that anti-PD-1 therapy, in addition
toderegulating T-cell-specific immunecheckpoint functions,may
also inhibit complementary protumorigenic mechanisms, thereby
contributing to its superior clinical efficacy compared to CTLA-4
blockade. Because PD-1 is not only expressed by immune cells,
but also by melanoma subpopulations with enhanced tumorige-
nicity, even in highly immunocompromised tumor xenograft
recipient mice (Schatton et al., 2010), we hypothesized that the
growth-suppressive effects of PD-1 therapy might also partially
result from the direct inhibition of this protein on melanoma cells.
Here, we report that established human andmurinemelanoma
cell lines as well as clinical melanomas frequently contain PD-1-
expressing cancer subpopulations and that enforcedmelanoma-
PD-1 expression enhances melanoma growth, even in the
absence of adaptive immunity. Conversely, antibody-mediated
melanoma-PD-1 blockade and melanoma-specific PD-1 knock-
down, as well as mutagenesis of melanoma-PD-1 signaling
motifs inhibit tumor growth independently of adaptive immunity.
Efficient melanoma-PD-1-driven tumorigenesis requires mela-
noma-PD-1 interactions with its predominant ligand, PD-L1,
which activate effectors of the mTOR signaling pathway down-
stream of the melanoma-PD-1 receptor. Our results expand
our current understanding of PD-1 pathway functions in mela-
noma and suggest that cancer cell-intrinsic PD-1 targeting
might significantly contribute to the therapeutic efficacy of
PD-1 antibodies, rendering PD-1 inhibition, in conjunction with
itsdemonstratedeffecton immunecheckpoint blockade, superior
to alternative therapies that target immune checkpoints alone.
RESULTS
Melanomas Frequently Contain PD-1-Expressing
Cancer Subpopulations
We first examined PD-1 expression in a series of melanoma
patient samples and established melanoma cell lines to further
expand upon the potential clinical significance of our previousCdemonstration that melanoma cells can express PD-1 (Schatton
et al., 2010). Flow cytometric analysis of single-cell suspensions
derived from clinical tumor specimens (n = 8 patients) revealed
PD-1 surface protein expression by melanoma subpopulations
negative for the pan-lymphocyte marker, CD45, and the endo-
thelial marker, CD31, in 8/8 melanoma specimens examined,
with tumor cell frequencies ranging from 3.5% to 16.5% (cell fre-
quency 8.7% ± 1.5%, mean ± SEM, Figure 1A and Figure S1A).
Immunofluorescence double labeling of clinical melanoma bi-
opsies (n = 50) for PD-1 and the melanoma antigen recognized
by T cells (MART)-1 further confirmed PD-1 protein expression
by subpopulations of MART-1+ melanoma cells that were cyto-
logically distinct from CD45+ lymphocytes (Figure 1B), with
n = 22/36 melanoma patients demonstrating melanoma-PD-1
positivity in at least one of their tumor lesions (Table S1).
Based on our intention to mechanistically dissect the role
of melanoma-expressed PD-1 in experimental tumor growth,
we next characterized PD-1 expression in established human
and murine melanoma cell lines. RT-PCR amplification and
sequencing of the full coding sequence (CDS) of the human
PD-1 (PDCD1) gene revealed PDCD1 mRNA expression (Fig-
ure 1C), and immunoblot analysis demonstrated PD-1 protein
expression by human A375, C8161, and G3361 melanoma cells
(Figure 1D). Flow cytometric analyses showed PD-1 surface
protein expression by 8/8 melanoma lines tested, with PD-1+ tu-
mor cell frequencies ranging from 11.3% ± 1.2% to 29.5% ±
3.7% (mean ± SEM, Figure 1E), and revealed preferential PD-1
expression bymelanoma cell subsets positive for the tumor-initi-
ating cell determinant (Schatton et al., 2008), ABCB5 (Figures
S2A–S2C), consistent with our previous demonstration of PD-1
expression by melanoma-initiating cells (Schatton et al., 2010).
Human melanoma lines also demonstrated positivity for both
PD-1 ligands, PD-L1 and PD-L2, ranging from 2.4% ± 0.1% to
99.2% ± 0.1% and 0.6% ± 0.1% to 88.9% ± 2.6% of cells
(mean ± SEM), respectively (Figure S1B), and PD-1 co-expres-
sion with its ligands (not shown). Murine B16-F0 and B16-F10
cultures also expressed both PD-1 (Pdcd1) mRNA, as deter-
mined by amplification and sequencing of the full Pdcd1 CDS
(Figure 1F), and PD-1 protein as determined by immunoblotting
(Figure 1G). Flow cytometric analysis revealed PD-1 (cell fre-
quency 9.4% ± 2.5% and 6.6% ± 2.4%,mean ± SEM, Figure 1H)
and PD-L1 (43.4% ± 9.4% and 37.5% ± 2.3%), but not PD-L2
surface protein expression by B16-F0 and B16-F10 melanoma
cells (Figure S1C). B16 melanoma grafts grown in non-obese
diabetic severely combined immunodeficient (NOD/SCID) inter-
leukin-2 receptor (IL-2R) g-chain(/) null (NSG) mice lacking
adaptive immunity also demonstrated PD-1 expression by
MART-1+ melanoma cells (Figure 1I).
Melanoma-Expressed PD-1 Promotes Murine Tumor
Growth
To functionally dissect the potential role ofmelanoma-expressed
PD-1 in tumor growth, we generated stable Pdcd1 knockdown
(KD) and Pdcd1-overexpressing (OE) B16 melanoma lines.
Transduction of B16-F0 andB16-F10 cells with two distinct short
hairpin (sh) RNAs targeting Pdcd1 inhibited murine PD-1 mRNA
expression by R59% and significantly blocked PD-1 protein
expression compared to controls (Figure 2A), but did notell 162, 1242–1256, September 10, 2015 ª2015 Elsevier Inc. 1243
Figure 1. PD-1 Expression by Melanoma Cells
(A) Percentages (mean ± SEM) (left) and representative flow cytometry plots
(right) of PD-1 surface protein expression by clinical tumor biopsy-derived
melanoma cells (green) from n = 8 distinct melanoma patients. These cells are
negative for the CD45 lymphocyte common antigen (red) and the CD31
endothelial marker (see also Figure S1A).
(B) Representative immunofluorescence double staining of a clinical mela-
noma biopsy for co-expression of PD-1 (green) and MART-1 (red) or of PD-1
(green) and CD45 (red) on a serial tissue section. Nuclei were counterstained
with DAPI (blue). Size bars, 100 mm. Representative of n = 22/36 melanoma
patients demonstrating melanoma-PD-1 positivity. A patient was considered
1244 Cell 162, 1242–1256, September 10, 2015 ª2015 Elsevier Inc.significantly alter expression of PD-L1 or PD-L2, respectively
(not shown). Conversely, transduction of B16 cells with Pdcd1-
encoding constructs resulted in upregulation of PD-1, both at
the mRNA and protein level (Figure 2B). Melanoma-specific
Pdcd1-KD resulted in decreased and Pdcd1-OE in increased
B16-F0 and B16-F10 melanoma growth in immunocompetent
C57BL/6 mice compared to that of vector controls (Figure 2C).
Pdcd1-KD melanoma grafts demonstrated diminished (Fig-
ure S3A) and Pdcd1-OE melanomas significantly enhanced
Pdcd1mRNA and PD-1 protein expression compared to control
tumors at the experimental endpoint (Figure S3B). We next
compared the tumorigenic ability of native PD-1+- versus
PD-1-sorted B16-F0 and B16-F10 melanoma cells and found
that PD-1+ subpopulations demonstrated significantly increased
growth in C57BL/6 mice compared to PD-1 cells (Figure S3C).
Together, these findings identify melanoma-expressed PD-1 as
a protumorigenic mechanism.
PD-1 expressed by cells of the adaptive immune system
has been established as a modulator of tumor-specific immunity
(Topalian et al., 2012a). To determine whether the observed
tumor growth-accelerating effects of melanoma-expressed
PD-1 depend on melanoma-PD-1:lymphocyte interactions, we
compared the abilities of Pdcd1-KD and Pdcd1-OE versus
control B16 melanomas to initiate tumor growth in immunocom-
promised, T-, and B-cell-deficient NSG mice. We found that
Pdcd1-KD inhibited and Pdcd1 overexpression increased
tumorigenicity of B16-F0 and B16-F10 melanomas in NSG
mice compared to controls (Figure 2D), suggesting lympho-
cyte-independent roles of melanoma-PD-1 in tumorigenesis.
Significant Pdcd1-KD (Figure S4A) and overexpression (Fig-
ure S4B) in B16 melanoma grafts was confirmed after in vivo
growth. Consistent with our findings usingPdccd1-overexpress-
ing melanoma variants, we found that PD-1+ melanoma sub-
populations purified from native B16-F0 and B16-F10 lines
demonstrated increased tumorigenicity in NSG mice compared
to PD-1 cell isolates (Figure S4C).
We next examined whether melanoma-specific Pdcd1
silencing or overexpression affects melanoma cell growth
in vitro, in the complete absence of immune cells, using anmelanoma-PD-1 positive if any tumor biopsy (total of n = 50) showed
expression of PD-1 by MART-1+ and/or CD45 cells. See also Table S1.
(C and D) RT-PCR expression analysis (C) of full-length PD-1 (PDCD1) mRNA
and (D) immunoblot of PD-1 protein expression by human melanoma lines and
PBMCs.
(E) Percentages (mean ± SEM, left) and representative flow cytometry plots
(right) of PD-1 surface protein expression by human melanoma lines (n = 3–4
independent experiments, respectively).
(F and G) RT-PCR expression analysis (F) of full-length PD-1 (Pdcd1)
mRNA and (G) immunoblot of PD-1 protein expression by murine B16-F0
and B16-F10 melanoma cells, wild-type (WT), and Pdcd1 knockout (KO)
C57BL/6-derived splenocytes.
(H) Percentages (mean ± SEM, left) and representative flow cytometry plots
(right) of PD-1 surface protein expression by B16 cells (n = 4–6 independent
experiments, respectively).
(I) Representative PD-1 immunohistochemistry and immunofluorescence
double staining for co-expression of PD-1 (green) with MART-1 (red) (inset
photomicrograph) of a B16-F10 melanoma graft grown in NSG mice (size bar,
50 mm).
See also Figures S1 and S2, and Table S1.
Figure 2. Melanoma-Expressed PD-1 Promotes Tumorigenicity in Murine Melanoma Models
(A and B) PD-1 mRNA and protein expression by Pdcd1-shRNA-1 and Pdcd1-shRNA-2 versus vector control (A) and by Pdcd1-overexpressing (OE) versus
vector-control B16-F0 or B16-F10 melanoma cells (B). Representative flow cytometry plots show PD-1 expression in B16-F10 melanoma variants.
(C and D) Tumor growth kinetics (mean ± SD) of Pdcd1-shRNA-1/-2 versus Pdcd1-OE versus vector control B16-F0 or B16-F10 melanomas in C57BL/6 mice
(n = 10–30 each) (C) or NSG mice (n = 10–20 each) (D).
(E and F) Mean number of tumor spheres ± SEM (left) and immunoblot analysis of phosphorylated (p) and total S6, AKT, and ERK (right) in Pdcd1-shRNA-1
and Pdcd1-shRNA-2 versus control (E) and Pdcd1-OE versus vector-control B16 melanoma variants (F). Results are representative of n = 2–3 independent
experiments (**p < 0.01, ***p < 0.001).
See also Figures S3 and S4.established culture system designed for the study of tumorigenic
minority populations (Aceto et al., 2012; Civenni et al., 2011).
Consistent with our in vivo findings, Pdcd1-KD impaired (Fig-
ure 2E) and Pdcd1-OE promoted in vitro three-dimensionalCB16-F0 and B16-F10 culture growth compared to respective
controls (Figure 2F). Because PD-1 receptor signaling in T cells
modulates several downstream pathways (Riley, 2009) that
also serve critical roles in melanomagenesis (Flaherty et al.,ell 162, 1242–1256, September 10, 2015 ª2015 Elsevier Inc. 1245
Figure 3. Tumor Cell-Intrinsic PD-1 Signaling Promotes Murine Melanoma Growth
(A) Growth kinetics (mean ± SD) of Pdcd1-OE versus vector control B16-F10 melanomas in PD-L1(/) KO Rag(/) KO (n = 14 versus 20 versus 10) versus
wild-type Rag(/) KO recipients (n = 14 versus 14 versus 8) treated with anti-PD-L1- versus isotype control monoclonal antibody (mAb).
(B) Growth kinetics (mean ± SD) in C57BL/6 (left) and NSGmice (right) of Pdcd1-OE B16-F10 cells co-transduced with PD-L1 (Cd274, also known as Pdcd1lg1)-
shRNA versus control-shRNA compared to vector controls (n = 10 each).
(legend continued on next page)
1246 Cell 162, 1242–1256, September 10, 2015 ª2015 Elsevier Inc.
2012), such as MAPK/ERK, PI3K/AKT, and mTOR signaling, we
next examined melanoma-Pdcd1-specific changes in phospho
(p)-ERK1/2, p-AKT, and p-S6 ribosomal protein levels. Pdcd1-
KD reduced (Figure 2E) and Pdcd1-OE increased phosphoryla-
tion of the mTOR effector molecule, S6, compared to control
B16 melanoma cells (Figure 2F), indicating melanoma cell-
intrinsic, PD-1-mediated induction of protumorigenic mTOR
pathway activity. Together, these in vitro findings suggest
lymphocyte-independent, cancer cell-intrinsic functions of mel-
anoma-expressed PD-1 in tumor growth.
Melanoma-PD-1:PD-L1 Interactions Promote Murine
Melanoma Growth
Wenext examinedwhether ligation ofmelanoma-PD-1 to its pre-
dominant ligand, PD-L1, is required for PD-1-driven tumorigen-
esis. To test whether melanoma-PD-1:host-PD-L1 interactions
promote tumor growth in the absence of adaptive immunity,
we grafted Pdcd1-OE versus control B16-F10 cells to wild-
type Rag(/) versus PD-L1(/) KO Rag(/) mice (Francisco
et al., 2009). We found that the growth of Pdcd1-OE melanomas
was attenuated in PD-L1(/) KO Rag(/) compared to
PD-L1(+/+) Rag(/) recipients (Figure S5A). To examine if
PD-L1 expressed bymelanoma cells (Figure S1) also contributes
to melanoma-PD-1-dependent tumorigenesis, we treated
PD-L1(/) KO Rag(/) versus wild-type Rag(/) mice
grafted with Pdcd1-OE melanomas with a PD-L1 blocking
antibody. We found that PD-L1 blockade inhibited Pdcd1-OE
B16-F10 melanoma growth compared to isotype control anti-
body treatment in PD-L1(/) KO mice (Figure 3A). Additionally,
PD-L1 antibody treatment resulted in significantly reduced tumor
growth of Pdcd1-OE melanomas in PD-L1(/) KO Rag(/)
compared to wild-type Rag(/) mice (Figure 3A). These
findings suggest growth-accelerating functions not only of
host-PD-L1:melanoma-PD-1, but also of melanoma-PD-L1:
melanoma-PD-1 interactions.
To further demonstrate protumorigenic melanoma-PD-L1
effects in the absence of adaptive immunity, we generated
PD-L1 gene (Cd274, also known as Pdcd1lg1)-KD B16-F10 mel-
anoma cells (Figure S5B) and tested their ability to maintain
culture growth and form tumors. Compared to vector controls,
Pdcd1lg1 silencing impaired three-dimensional B16 melanoma
growth in vitro (Figure S5C) and in vivo tumorigenesis in both
immunocompetent C57BL/6 and immunocompromised NSG
mice (Figure S5D). Moreover, Pdcd1lg1-KD reversed the signif-
icant increase in tumorigenicity of Pdcd1-OE versus vector
control B16-F10melanoma cells in C57BL/6 and NSGmice (Fig-
ure 3B). To further demonstrate that PD-L1 interactions with
melanoma-PD-1 promote melanoma growth, we treated native(C) Mean number of tumor spheres ± SEM (left), and immunoblot analysis of p- a
(right).
(D) Immunoblot analysis of p- and total S6, AKT, and ERK in PD-L1 Ig versus
pharmacologic PI3K inhibitors, wortmannin or LY294002, or the mTOR pathway
(E) Schematic diagram illustrating the introduction of tyrosine to phenylalanine m
(F) Relative Pdcd1 mRNA expression (top, mean ± SEM) and representative flo
Pdcd1-OE versus Y225F-Pdcd1-OE, Y248F-Pdcd1-OE, Y225F/Y248F-Pdcd1-O
(G–I) Tumor growth kinetics (G) in C57BL/6 (top, n = 10–14 each) and NSG mic
immunoblot analysis of p- and total S6, AKT, and ERK in B16-F10 melanoma v
experiments, respectively (*p < 0.05, **p < 0.01, ***p < 0.001). See also Figure S
CB16-F0 and B16-F10 cultures with a recombinant PD-L1 Fc-fu-
sion protein (PD-L1 Ig), known to elicit changes in PD-1 receptor
signaling in T cells (Francisco et al., 2009). Compared to control
Ig treatment, addition of PD-L1 Ig to B16 cultures significantly
augmented three-dimensional growth and phosphorylation of
S6 ribosomal protein (Figure 3C). Because both PI3K/AKT and
mTOR signaling are known to feed into downstream S6 phos-
phorylation, we examined whether pharmacologic inhibition of
either pathway can reverse the observed increase in p-S6
expression. We found that mTOR pathway blockade (via rapa-
mycin or PP242) but not PI3K inhibition (via wortmannin or
LY294002) suppressed the PD-L1 Ig-dependent phosphoryla-
tion of S6 in murine B16-F10 melanoma cells (Figure 3D).
Together, these findings demonstrate that interactions between
melanoma-expressed PD-1 with its ligand, PD-L1, promote tu-
mor growth and activate mTOR signaling.
Tumor Cell-Intrinsic PD-1 Signaling Is Required for
Efficient Murine Melanoma Growth
To determine whether melanoma cell-intrinsic PD-1 signaling is
required for efficient tumor growth, we generated Pdcd1-OE
B16 variants containing tyrosine to phenylalanine single-point
mutationsof twoPD-1signalingmotifs, the immunoreceptor tyro-
sine-based inhibitory motif (ITIM, disrupted by Y225F mutation)
and the immunoreceptor tyrosine-based switchmotif (ITSM, dis-
rupted by Y248F mutation), within the cytoplasmic tail of mela-
noma-PD-1 (Figure 3E). A construct containing point mutations
of both tyrosines (Y225F/Y248F) was also created. In immune
cells, ITIM and ITSM play pivotal roles in PD-1 signaling (Riley,
2009). Transductionofwild-typeversusmutantPdcd1constructs
into B16-F0 or B16-F10 melanoma cells resulted in similarly high
expression levels of PD-1 (Figure 3F andFigureS5E), permitting a
direct comparison between wild-type Pdcd1-OE and each of the
mutant variants. Strikingly, mutation of either one (Y225F or
Y248F) or both (Y225F/Y248F) melanoma-PD-1 signaling motifs
significantly abrogated the increased tumor growth observed in
both C57BL/6 and NSG mice grafted with wild-type Pdcd1-OE
versus vector-control B16melanomavariants (Figure 3GandFig-
ure S5F), suppressed three-dimensional tumor growth in vitro
(Figure 3H and Figure S5G), and phosphorylation of S6 ribosomal
protein (Figure 3I) compared to enforced expression of wild-type
Pdcd1, respectively.
Melanoma Cell-Intrinsic PD-1 Enhances Human Tumor
Xenograft Growth
We next analyzed the effects of melanoma-specific PD-1 knock-
down versus PD-1 overexpression on human melanoma xeno-
graft growth. Transduction of human A375, C8161, or G3361nd total S6, AKT, and ERK in PD-L1 Ig versus control Ig-treated B16 cultures
control Ig-treated B16-F10 melanoma cells cultured in the presence of the
inhibitors, rapamycin or PP242.
utations to murine PD-1 signaling motifs via site-directed mutagenesis.
w cytometry plots of PD-1 surface protein expression (bottom) by wild-type
E, and vector-control B16-F10 variants.
e (bottom, n = 8–10 each), (H) mean number of tumor spheres ± SEM, and (I)
ariants as in (F). Immunoblot results are representative of n = 2 independent
5.
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(legend on next page)
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melanoma cells with two distinct PDCD1-shRNAs significantly
inhibited PD-1 mRNA expression and blocked PD-1 protein
expression between 53%–75% (Figure S6A), and infection with
PDCD1-OE constructs resulted in marked upregulation of
PD-1, both at the mRNA and protein level (>90% positivity),
respectively (Figure S6B). PDCD1-KD significantly inhibited
and PDCD1-OE markedly increased human melanoma xeno-
graft growth in NSG mice compared to vector-control-trans-
duced A375, C8161, or G3361 tumors (Figure 4A). Preservation
of PDCD1 silencing and overexpression were confirmed for all
melanoma xenografts at the experimental endpoint, respectively
(Figures S6C and S6D). Moreover, PD-1+ cancer cell subsets pu-
rified from native C8161 cultures showed significantly increased
tumorigenicity in NSG mice, compared to PD-1 C8161 cells
(Figure S6E). Consistent with our in vivo findings, PDCD1-KD
impaired and PDCD1-OE promoted three-dimensional A375,
C8161, and G3361 culture growth compared to controls (Fig-
ure 4B). Furthermore, relative to control Ig treatment, addition
of human PD-L1 Ig augmented tumor sphere formation of
A375 and G3361, but not C8161 melanoma cultures (Figure 4B),
the latter of which express greater than 3-fold higher endoge-
nous PD-L1 levels than A375 and G3361 cells (Figure S1B).
Similar to our findings in murine B16 cells, human PDCD1-KD
lines showed a reduction and PDCD1-OE and PD-L1 Ig-treated
human G3361 melanoma cells an increase in p-S6 levels
compared to respective controls (Figure 4C). Additionally, phar-
macologic inhibition of mTOR but not PI3K signaling blocked the
increase in p-S6 expression in PD-L1 Ig compared to control Ig-
treated human G3361 melanoma cells (Figure 4D), indicating
mTOR pathway dependence of S6 phosphorylation downstream
of the melanoma-PD-1 receptor, consistent with our findings in
murine B16 melanoma cells (Figure 3D).
Furthermore, generation of human PDCD1-OE ITIM (Y223F)
and/or ITSM (Y248F) mutant A375 and C8161 cell lines (Fig-
ure 4E) with similarly high expression levels of human PD-1 (Fig-
ure 4F) revealed that mutation of either one (Y223F or Y248F) or
both (Y223F/Y248F) signaling motifs within the melanoma-PD-1
cytoplasmic tail abrogated the increased tumor growth observed
in mice grafted with wild-type PDCD1-OE versus vector-control
A375 or C8161 variants (Figure 4G). Additionally, Y223F-,
Y248F-, and Y223F/Y248FmutantPDCD1-OEC8161melanoma
cells demonstrated significantly impaired three-dimensional
culture growth (Figure 4H) and reduced p-S6 levels comparedFigure 4. PD-1 Expression by Human Melanoma Cells Promotes Expe
(A) Tumor growth kinetics (mean ± SD) of PDCD1-shRNA-1, PDCD1-shRNA-2,
G3361 melanoma cells (right) grafted to NSG mice (n = 8–20 each).
(B) Mean number of tumor spheres ± SEM and (C) immunoblot analysis (G33
PDCD1-shRNA-1/-2 versus vector control, PDCD1-OE versus vector-control,
melanoma cultures.
(D) Immunoblot analysis of p- and total S6, AKT, and ERK in PD-L1 Ig versus c
macologic PI3K inhibitors, wortmannin or LY294002, or the mTOR pathway inhib
(E) Schematic diagram illustrating the introduction of tyrosine to phenylalanine m
(F and G) Representative flow cytometry plots (F) of PD-1 surface protein expres
PDCD1-OE, Y248F-PDCD1-OE, Y223F/Y248F-PDCD1-OE, and vector-control h
mice, respectively.
(H and I) Mean number of tumor spheres (H) ± SEM and (I) immunoblot analys
Immunoblot results are representative of n = 2–3 independent experiments (*p <
See also Figure S6.
Cto wild-type PDCD1-OE C8161 cells (Figure 4I). Together, these
findings identify PD-1 expressed by human melanoma cells
as a lymphocyte-independent tumor growth-accelerating
mechanism.
Antibody-Mediated Blockade of PD-1 on Melanoma
Cells Inhibits Murine Melanoma Growth
We next examined whether antibody-mediated melanoma-PD-1
blockade significantly inhibits tumor growth, even in immuno-
compromised NSG hosts, as would be expected based upon
the herein demonstrated melanoma cell-intrinsic, protumori-
genic PD-1 receptor functions. First, administration of a PD-1
blocking antibody to immunocompetent, C57BL/6 recipients
starting one day before inoculation with B16-F10 cells resulted
in modest inhibition of melanoma growth between days 5 and
11 post inoculation (p < 0.01), but showed no significant
differences in tumorigenicity compared to isotype control anti-
body-treatment at later time points (Figure 5A), consistent with
previous studies (Peng et al., 2012; Woo et al., 2012). However,
we found that antibody-mediated PD-1 blockade significantly
(p < 0.05) inhibited B16-F10 melanoma growth in PD-1(/)
KO C57BL/6 mice compared to controls, for the entire duration
of the experiment (Figure 5B). Immunohistochemical examina-
tion of melanoma grafts harvested at the experimental endpoint
revealed >5-fold increased binding (p < 0.05) of in vivo-adminis-
tered anti-PD-1 antibody to B16 melanoma target tissue in
PD-1(/) KO (Figure 5B) compared to wild-type C57BL/6 hosts
(Figure 5A), supporting the notion of a more pronounced
PD-1 antibody effect on melanoma cells in PD-1(/) KO
mice. A >20% increase in PD-1 antibody titer in the serum of
PD-1(/) KO versus PD-1(+/+) C57BL/6 hosts, as determined
by rat-IgG2a-specific ELISA (Figure S7A), further indicated that
increased PD-1 antibody availability might, at least in part,
contribute to the growth-inhibitory effect of PD-1 blockade in
PD-1(/) KO hosts. Anti-PD-1 antibody administration to
NSGmice also significantly (p < 0.001) diminished B16-F10 mel-
anoma growth compared to isotype control antibody treatment
(Figure 5C). Interestingly, while compared to B16 melanoma
grafts grown in C57BL/6 mice, B16 melanomas grafted to NSG
mice tended to show increased anti-PD-1 antibody binding, anti-
body titerswere not increased inNSGmouse serum (FigureS7A),
suggesting strain-specific differences in PD-1 antibody kinetics.
To control for the possibility that the observed growth-inhibitoryrimental Tumor Growth
and PDCD1-OE versus vector control human A375 (left), C8161 (center), and
61) of phosphorylated (p) and total ribosomal protein S6, AKT, and ERK in
and PD-L1 Ig- versus control Ig-treated human A375, C8161, and G3361
ontrol Ig-treated G3361 melanoma cells cultured in the presence of the phar-
itors, rapamycin or PP242.
utations to human PD-1 signaling motifs via site-directed mutagenesis.
sion and (G) tumor growth kinetics (mean ± SD) of PDCD1-OE versus Y223F-
uman A375 (top, n = 10–24) and C8161 melanomas (bottom, n = 10–12) in NSG
is of p- and total S6, AKT, and ERK in C8161 melanoma variants as in (D).
0.05, **p < 0.01, ***p < 0.001).
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Figure 5. Anti-PD-1 Blocking Antibody Inhibits Murine Melanoma Growth in Immunocompetent, Immunocompromised and PD-1-Deficient
Tumor Graft Recipient Mice
(A–E) Tumor growth kinetics (A) (mean ±SD) of B16-F10melanomas in wild-type C57BL/6 (n = 32 versus 34), (B) PD-1(/) knockout (KO) C57BL/6 (n = 20 versus
16), and (C) NSG (n = 20 versus 18), and of (D) Pdcd1-overexpressing (OE) versus vector control B16-F10 melanomas in C57BL/6 (n = 10 each) or (E) NSG mice
(n = 10 each) treated with anti-PD-1- versus isotype control antibody. Representative immunohistochemical images illustrate binding of in vivo-administered rat
anti-mouse PD-1 blocking but not isotype control antibody to the respective B16-F10 melanoma grafts (size bars, 50 mm).
(F and G) Mean number of tumor spheres ± SEM (F) and (G) flow cytometric assessment of cell death (percent AnnexinV+/7AAD+ cells, mean ± SEM (left) and
representative flow cytometry plots (right) of anti-PD-1- versus isotype control mAb-treated murine B16-F0 and B16-F10 melanoma cultures.
(H) Immunoblot analysis (representative of n = 2 independent experiments) of phosphorylated (p) and total ribosomal protein S6, AKT, and ERK in B16 cultures
concurrently treated with PD-L1 Ig versus control Ig and/or anti-PD-1- versus isotype control mAb (NS: not significant, *p < 0.05, **p < 0.01, ***p < 0.001).
See also Figure S7.
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effects might result from antibody-mediated blockade of PD-1-
expressing innate immune cell subtypes present in NSG mice,
we administered anti-PD-1 antibody to NK cell-, macrophage-,
and neutrophil-depleted NSG recipients of B16-F10 melanoma
cells (Figure S7B). We also generated NSG mice depleted of
all three innate immune effector subsets. Anti-PD-1 antibody
treatment inhibited B16 melanoma growth compared to isotype
control antibody in all innate immune cell-depleted NSG hosts
(Figure S7C).
To further confirm melanoma-specific PD-1 inhibition of the
PD-1 blocking antibody, we administered anti-PD-1 antibody
to C57BL/6 and NSGmice grafted with Pdcd1-OE versus vector
control B16-F10 melanoma cells. Anti-PD-1 antibody treatment
reversed the increase in tumor growth of isotype control-treated
Pdcd1-OE compared to vector-control B16 melanomas in both
C57BL/6 (Figure 5D) and NSG mice, concomitant with binding
of in vivo-administered anti-PD-1 antibody to B16 melanomas
(Figure 5E), thereby confirming recognition of melanoma-PD-1
by the PD-1 blocking antibody. Antibody-mediated PD-1
blockade also reduced three-dimensional B16-F0 and B16-F10
melanoma growth in vitro (Figure 5F), but did not induce signifi-
cant cell death compared to isotype control antibody-treatment
(Figure 5G). Moreover, treatment of B16 melanoma cultures with
anti-PD-1 but not isotype control antibody inhibited phosphory-
lation of S6 ribosomal protein (Figure 5H). Together, these find-
ings show that antibody-mediated PD-1 blockade directly on
melanoma cells inhibits tumor cell-intrinsic, protumorigenic
PD-1 functions, including in the absence of adaptive immunity.
Antibody-Mediated PD-1 Blockade Inhibits Human
Melanoma Xenograft Growth in Immunodeficient Mice
We next examined whether antibody-mediated PD-1 blockade
can also inhibit human melanoma growth in NSG mice. To
assess the translational relevance of targeting melanoma cell-
intrinsic PD-1 to impede tumor growth, we first administered
anti-PD-1 antibody to NSG mice grafted with patient-derived
melanoma cells. Consistent with our findings in murine B16
models (Figure 5C), in vivo anti-PD-1 antibody administration
to NSG mice significantly inhibited mean tumor volumes of
clinical melanoma xenografts derived from three distinct mela-
noma patients (Figure 6A). Anti-PD-1 antibody treatment also
significantly inhibited the growth of human A375, C8161, and
G3361 melanoma xenografts in NSG mice compared to that of
the respective control antibody-treated melanomas (Figure 6B).
Immunohistochemical analysis revealed binding of in vivo-
administered anti-human PD-1 antibody to melanoma xeno-
grafts (Figure 6C). Administration of anti-PD-1 antibody to NSG
mice also abrogated the increased melanoma xenograft
growth of isotype control-treated human PDCD1-OE compared
to vector-control C8161 xenografts (Figure 6D). Marked
melanoma binding of in vivo-administered anti-PD-1 antibody
to PDCD1-OE C8161 melanomas (Figure 6D) confirmed mela-
noma-PD-1 reactivity of the human anti-PD-1 blocking anti-
body. Compared to isotype control antibody-treatment, PD-1
blockade also decreased three-dimensional melanoma growth
in vitro (Figure 6E), but did not significantly induce apoptosis in
human A375, C8161, or G3361 melanoma cultures (Figure 6F).
Finally, treatment of G3361 melanoma cells with anti-PD-1 butCnot isotype control antibody inhibited PD-L1 Ig-dependent
phosphorylation of S6 ribosomal protein (Figure 6G). Together,
our findings in NSG mice indicate that anti-PD-1-mediated mel-
anoma growth inhibition results from direct interference with
melanoma-expressed PD-1 and is not necessarily dependent
on adaptive immunity.
Melanoma Cell Expression of the PD-1 Effector
Molecule, p-S6, Correlates with Response to PD-1
Therapy in Cancer Patients
To further assess the translational relevance of melanoma cell-
intrinsic PD-1 receptor signaling, we performed p-S6 staining
and quantitatively assessed melanoma-p-S6 positivity in pre-
treatment versus post-treatment tumor biopsies obtained from
n = 11 melanoma patients undergoing anti-PD-1 therapy. We
found that melanoma biospecimens sampled post PD-1 therapy
demonstrated significantly (p = 0.005) decreased p-S6 expres-
sion compared to patient-matched pre-treatment biopsies (Fig-
ure 7A), consistent with our findings in PD-1 antibody-treated
melanoma cell lines (Figures 5H and 6G). Additionally, in a cohort
of n = 34 melanoma patients where pre-treatment tumor tissue
was available for analysis, we found that patients with high
p-S6 expression (>25% of melanoma cells, Figure 7B) prior to
treatment showed a >3-fold increase in progression-free survival
(mean progression-free survival: 17.0 versus 4.5 months, p =
0.001, Figure 7C) and significantly (p < 0.05) enhanced overall
survival (mean overall survival: 25.1 versus 13.0 months, Fig-
ure 7D) compared to melanoma patients with low p-S6 levels
(<25% of melanoma cells, Figure 7B) in pre-treatment tumor
biospecimens (Table S2). These findings suggest a relationship
between p-S6 and response to PD-1 pathway blockade, thereby
indicating the potential translational relevance of melanoma cell-
intrinsic PD-1 receptor functions.
DISCUSSION
Our study provides several insights into PD-1 pathway functions
in melanoma. First, we have conducted a comprehensive
characterization of PD-1 transcript and protein expression by
cancer cells in clinical tumor biopsies and establishedmelanoma
lines. Until now, PD-1 expression has beenmainly reported in im-
mune-competent cells of the hematopoietic lineage (Topalian
et al., 2012a). We found that both melanoma cell lines and surgi-
cal specimens frequently harbor PD-1-expressing cancer cells.
However, PD-1 is not uniformly present on all melanoma cells
among heterogeneous tumor samples. Rather, it is restricted
to small melanoma subpopulations that are nonetheless critically
important for tumor growth, consistent with our previous findings
demonstrating preferential PD-1 expression by melanoma-
initiating cells (Schatton et al., 2010). In our current study, RT-
PCR, immunoblot, and flow cytometric analyses revealed PD-1
on melanoma cells in all cell lines and clinical tumor samples
examined. Furthermore, immunofluorescence double labeling
similarly showed PD-1 expression by melanoma subpopulations
in clinical biopsy specimens obtained from >60% of melanoma
patients. Thus, using various independent methods, our work
clearly establishes that melanomas frequently contain PD-1+ tu-
mor cell fractions. Comparably, melanoma cell expression of theell 162, 1242–1256, September 10, 2015 ª2015 Elsevier Inc. 1251
Figure 6. Anti-PD-1 Blocking Antibody Inhibits Human Melanoma Xenograft Growth in Immunocompromised Mice
(A) Kinetics (mean ± SD) of clinical melanoma xenograft growth in NSG mice treated with anti-human PD-1 or isotype control antibody (patient A, n = 7 each;
patient B, n = 5 versus 4; patient C: n = 10 each).
(B–D) Tumor growth kinetics (B) (mean ± SD) and (C) representative secondary antibody staining (size bars, 50 mm) of mouse anti-human PD-1 versus isotype
control antibody-treated human A375 (n = 14 each), C8161 (n = 14 each), or G3361 melanoma xenografts (n = 16 versus 12) or of (D) human PDCD1-OE versus
vector control-transduced C8161 xenografts in NSG mice (n = 10 each). Immunohistochemical images illustrate binding of in vivo-administered mouse anti-
human PD-1 blocking but not isotype control antibody to the respective human melanoma xenograft (size bars, 50 mm).
(E and F) Mean number of tumor spheres (E) ± SEM and (F) flow cytometric assessment of cell death (percent AnnexinV+/7AAD+ cells, mean ± SEM (left) and
representative flow cytometry plots (right) of anti-PD-1- versus isotype control mAb-treated human A375, C8161, and G3361 melanoma cultures.
(H) Immunoblot analysis (representative of n = 3 independent experiments) of phosphorylated (p) and total ribosomal protein S6, AKT, and ERK in G3361 cultures
concurrently treated with PD-L1 Ig versus control Ig and/or anti-PD-1- versus isotype control mAb (NS: not significant, *p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 7. Analysis of p-S6 Expression in Tu-
mor Biospecimens Obtained from Patients
with Advanced-Stage Melanoma Undergo-
ing anti-PD-1 Antibody Therapy
(A) Expression of phospho (p)-S6 ribosomal protein
by melanoma cells in tumor biospecimens ob-
tained from n = 11 patients with stage IVmelanoma
before treatment start compared to that in patient-
matched progressive lesions sampled after
initiation of anti-PD-1 antibody therapy. p-S6
expression by melanoma cells was determined
by immunohistochemical analysis and graded by
three independent investigators blinded to the
study outcome on a scale of 0–4 (0: no p-S6
expression by melanoma cells; 1: p-S6 expression
in 1%–25%; 2: 26%–50%; 3: 51%–75%; 4: >75%
of melanoma cells).
(B) Representative p-S6 immunohistochemistry of
tumor biospecimens obtained from melanoma
patients before initiation with systemic anti-PD-1
antibody therapy showing low (<25%) versus high
(>25%) melanoma cell expression of p-S6. Size
bars, 50 mm.
(C and D) Kaplan-Meier estimates (C) of progres-
sion-free survival and (D) of overall survival prob-
ability in stage IV melanoma patients (n = 34) demonstrating low (<25%, n = 14 patients) versus high melanoma cell-expression of p-S6 (>25%, n = 20 patients)
in tumor biospecimens obtained before initiation of systemic anti-PD-1 antibody treatment.
See also Table S2.PD-1 ligand, PD-L1, is often confined to small subsets of cancer
cells within clinical tumor specimens (Herbst et al., 2014; Topa-
lian et al., 2012b).
Second, this study demonstrates PD-1 receptor signaling in a
non-immune cell type, i.e., melanoma cells. To date, PD-1 immu-
nobiology has been mainly studied in T cells (Topalian et al.,
2012a). Binding of T-cell-expressed PD-1 to its ligandsmediates
inhibitory signals that downmodulate T effector functions. For
example, in the cancer context, PD-1 expression by tumor-reac-
tive CTLs results in their exhaustion or functional impairment
(Fourcade et al., 2010; Sakuishi et al., 2010), which represents
a key mechanism underlying tumor immune evasion (Pardoll,
2012). Similar to the protumorigenic effects of T-cell-expressed
PD-1, our findings establish PD-1 expressed by melanoma cells
as a tumor-growth-promoting mechanism in multiple indepen-
dent experimental in vitro and in vivo systems. However, while
T cell-PD-1 promotes cancer progression by dampening anti-
tumor immune responses, melanoma-PD-1 promotes tumor
growth, even in the absence of a functional adaptive immune
system.
Our results further indicate that efficient, PD-1-driven tumori-
genesis requires melanoma-PD-1 interactions with host- and/
or melanoma-expressed PD-L1, because both PD-L1-deficient
and PD-L1 antibody-treated mice grafted with Pdcd1-OE mela-
nomas demonstrate decreased tumor growth compared to
respective controls. Additionally, PD-L1 (Pdcd1lg1) silencing
reversed melanoma-PD-1-driven tumorigenesis and recombi-
nant PD-L1 Ig treatment promoted melanoma spheroid growth.
PD-L1 expression by melanoma cells has established roles in
tumor immune evasion (Dong et al., 2002). Beyond promoting
cancer progression by engaging with TIL-expressed PD-1, our
study indicates that melanoma-expressed PD-L1 may also pro-Cmote tumor growth via paracrine or autocrine interactions with
the melanoma-PD-1 receptor.
In T cells, PD-1 engagement by its ligandsmodulates signaling
networks downstream of the TCR, including mTOR and PI3K/
AKT (Riley, 2009). Consistent with the interrelationship of PD-1
and PI3K/AKT/mTOR signaling in T cells, the important role of
these pathways in melanoma proliferation (Flaherty et al.,
2012), and the herein described protumorigenic effects of
melanoma-PD-1, we found that PDCD1-KD, antibody-mediated
PD-1 blockade, and mutagenesis of melanoma-PD-1 signaling
motifs decreased, while PDCD1-OE and PD-L1 Ig-treatment
increased phosphorylation of the mTOR effector molecule
(Corcoran et al., 2013), ribosomal protein S6. Melanoma-PD-1-
dependent S6 phosphorylation was reversed via pharmacologic
inhibition of mTOR but not PI3K, suggesting that the PD-1 recep-
tor on melanoma cells activates downstream mTOR signaling
through a PI3K/AKT-independent pathway. However, whereas
PD-1 activation augments p-S6 levels in melanoma cells and en-
hances tumor growth, it dampens mTOR signaling in T cells,
leading to diminished proliferation (Riley, 2009). Because S6
phosphorylation represents a point of convergence that inte-
grates multiple upstream signaling networks (Corcoran et al.,
2013; Flaherty et al., 2012), it is possible that melanoma-PD-1
might also modulate several alternative signaling networks, in
addition to the mTOR pathway.
PD-1 ligation in T-lymphocytes is known to recruit phospha-
tases SHP-1 and SHP-2 to its ITIM and ITSM cytosolic loci,
which induces dephosphorylation of proximal TCR signaling in-
termediaries and subsequent suppression of several pathways
downstream of the TCR, including mTOR (Riley, 2009). SHP-2
is also expressed by melanoma cells (Ostman et al., 2006) and
tumor-initiating cell subsets in other cancers (Aceto et al.,ell 162, 1242–1256, September 10, 2015 ª2015 Elsevier Inc. 1253
2012; Liu et al., 2011), paralleling our previous findings of prefer-
ential PD-1 expression by melanoma-initiating cells (Schatton
et al., 2010). In cancer cells, SHP-2-dependent signaling pro-
motes activation of protumorigenic pathways, including mTOR
(Liu et al., 2011; Ostman et al., 2006). The divergent effects of
PD-1 ligation on mTOR signaling in melanoma cells versus
T cells are thus entirely consistent with the opposing, protumori-
genic versus growth-inhibitory roles of SHP-2 in the respective
tissues.
Finally, our work reveals that PD-1 pathway interference ex-
erts tumor growth-inhibitory effects, not only in mice with fully
intact immunity, but also inmelanoma cultures devoid of immune
cells and in severely immunocompromised, T cell-, B cell-, and
innate-immune-cell-deficient hosts. Together, these results
show that antibody-mediated blockade of PD-1 at the level of
themelanoma cell inhibits tumor growth. Because PD-1 pathway
inhibitors have produced unprecedented response rates in
otherwise treatment-refractory patients with advanced cancers,
including malignant melanoma (Hamid et al., 2013; Herbst et al.,
2014; Topalian et al., 2012b; Weber et al., 2015; Wolchok et al.,
2013), our findings are of potential translational importance.
It has been well established that PD-1 blockade reverses
cancer-antigen-specific T cell exhaustion, thereby restoring anti-
tumor immunity (Fourcade et al., 2010; Sakuishi et al., 2010).
Nevertheless, our data suggest that blockade of PD-1 directly
on melanoma cells might represent an important additional,
tumor cell-intrinsic mechanism that could contribute to the
clinical effectiveness of PD-1 cancer therapy. In support of this
possibility, our data obtained in a small cohort of patients with
stage IV melanoma suggests that tumoral expression of the
PD-1 receptor signaling mediator, p-S6, appears to correlate
with response to anti-PD-1 antibodies. However, the possible
utility of p-S6 as a potential biomarker of PD-1 inhibitor sensi-
tivity will require independent validation in larger patient cohorts,
including prospective cohort studies.
Consistent with our findings of protumorigenic effects of the
melanoma-PD-1:PD-L1 axis, clinical trial data suggest a correla-
tion between melanoma-PD-L1 and TIL-PD-L1 expression and
objective response to PD-1 checkpoint blockade (Herbst et al.,
2014; Topalian et al., 2012b; Tumeh et al., 2014). Interestingly,
both elevated PD-L1 (Jiang et al., 2013) and p-S6 expression
levels (Corcoran et al., 2013) have evolved as potential bio-
markers of resistance to melanoma therapies targeting onco-
genic BRAF mutations. Therefore, our data suggest that combi-
nation of therapies targeting the MAPK pathway (Flaherty et al.,
2012) with PD-1 inhibitors may be effective, not only because
they activate tumor-specific immunity while concurrently block-
ing the MAPK oncogenic pathway, but also because PD-1/
PD-L1 blockade might additionally suppress mTOR-associated
protumorigenic signals. Furthermore, in light of our findings,
the superior clinical activity and safety profile of anti-PD-1-
compared to anti-CTLA-4 therapy (Hamid et al., 2013; Pardoll,
2012; Postow et al., 2015; Weber et al., 2015) might, at least in
part, relate to the fact that the latter merely interferes with
T cell function, whereas PD-1 antibody treatment may also
directly target other PD-1-expressing immune cell types (Topa-
lian et al., 2012a) or the tumor itself, as suggested by our data.
Finally, robust clinical response to anti-PD-1 therapy in patients1254 Cell 162, 1242–1256, September 10, 2015 ª2015 Elsevier Inc.with cancers that have hitherto not typically responded to immu-
notherapy (Herbst et al., 2014; Topalian et al., 2012b) could at
least be partially explained by direct PD-1 inhibition on tumor
cells in the respective malignancies.
In summary, our findings identify PD-1 expressed by mela-
noma cells as a tumor growth receptor and molecular mediator
of melanoma cell-intrinsic mTOR signaling, serving to promote
tumorigenesis in addition to its protumorigenic role when ex-
pressedby immune cells. Recognition ofmelanoma-PD-1 recep-
tor-driven tumorigenesis critically enhances our understanding
of the mechanisms underlying melanoma progression and
could contribute to the further refinement of PD-1-targeted ther-
apies, for improved outcomes in patients with advanced stage
cancer.
EXPERIMENTAL PROCEDURES
Melanoma Cell Lines, Culture Methods, and Clinical Specimens
Melanoma cell lines were cultured as described (Schatton et al., 2008).
Human PBMCs were obtained from healthy volunteers and clinical tumor
biospecimens were obtained from melanoma patients in accordance with
protocols approved by the IRBs of Partners Health Care Management, the
Dana-Farber Cancer Institute, the University of Zurich, Switzerland, and the
University of Bern, Switzerland. Informed consent was obtained from all
subjects and all studies were conducted in accordance with the Declaration
of Helsinki. PD-1+ and PD-1 melanoma subpopulations were generated as
described (Schatton et al., 2008; Schatton et al., 2010).
RT-PCR, Real-Time qPCR, and Flow Cytometry
Full-length PDCD1 was amplified and sequenced following reverse transcrip-
tion of total mRNA using PDCD1-specific primer pairs. Relative PDCD1,
PDCD1LG1 (CD274), and PDCD1LG2 (CD273) transcript levels were deter-
mined by real-time qRT-PCR and calculated using the 2(DDCt) method (Schat-
ton et al., 2008; Schatton et al., 2010). PD-1 surface protein expression by
established melanoma lines and patient-derived melanoma single-cell sus-
pensions was analyzed by flow cytometry (Schatton et al., 2008; Schatton
et al., 2010).
Western Blot Analysis
Cells were lysed, total protein separated by SDS/PAGE and transferred to a
PVDF membrane by electroblotting (Posch et al., 2013). Expression levels of
human and murine PD-1 and of phosphorylated versus total ERK1/2, AKT,
and S6 proteins were determined using enhanced chemiluminescence (Posch
et al., 2013) or the Odyssey CLx imaging system (LI-COR Biosciences).
Immunohistochemistry and Immunofluorescence Staining
Immunofluorescence double labeling for PD-1, MART-1, and/or CD45, and
immunohistochemical analysis of PD-1 expression in experimental tumors
and of p-S6 expression in tumor biospecimens obtained from melanoma
patients undergoing anti-PD-1 antibody therapy were carried out as described
(Schatton et al., 2008; Schatton et al., 2010). p-S6 immunoreactivity by mela-
noma cells was graded by three independent investigators blinded to the
study outcome on a scale of 0–4 (0: no p-S6 expression by melanoma cells;
1: p-S6 expression in 1%–25%; 2: 26%–50%; 3: 51%–75%; 4: >75% of
melanoma cells).
Generation of Stable PD-1 or PD-L1 Knockdown and PD-1-
Overexpressing Melanoma Cell Line Variants
Stable PD-1 or PD-L1 knockdown melanoma lines were generated using
lentiviral transduction particles containing shRNAs against human PDCD1,
murine Pdcd1, or murine Pdcd1lg1 (Cd274), and PD-1-overexpressing mela-
noma lines by infection with viral particles containing the full-length murine
Pdcd1 or humanPDCD1CDS.PDCD1-OEmelanoma variants containing tyro-
sine to phenylalanine single-point mutations within PD-1 signaling motifs were
generated by site-directed mutagenesis followed by enforced expression, as
above.
Three-Dimensional Melanoma Culture
Melanoma tumor sphere cultures of native or melanoma-PD-1 variant lines
weremaintained, as described (Aceto et al., 2012; Civenni et al., 2011), in stan-
dard culturemedium, as above, in the presence or absence of anti-PD-1 or iso-
type control mAb, recombinant PD-L1 Ig or control Ig.
Murine Melanoma Induction and Human Melanoma
Xenotransplantation
C57BL/6, PD-1(/) KO C57BL/6, NSG, Rag(/), and PD-L1(/) KO
Rag(/) mice (Francisco et al., 2009) were maintained and experiments per-
formed in accordance with IACUC approved experimental protocols. For
tumorigenicity studies, melanoma cells were injected subcutaneously into
flanks of recipient mice (Schatton et al., 2008). For PD-1 and PD-L1 targeting
experiments melanoma cells were grafted, mice intraperitoneally injected with
anti-PD-1, anti-PD-L1, or isotype control mAbs (200 mg, respectively) every
other day starting one day before melanoma inoculation and tumor forma-
tion/growth assessed as described (Schatton et al., 2008).
Statistical Analysis
Gene and protein expression levels, tumor spheroid, and in vivo melanoma
growth were compared statistically using the unpaired Student’s t test, the
nonparametric Mann-Whitney test (comparison of two experimental groups)
or repeated-measures two-way ANOVA followed by the Bonferroni correction
(comparison of three or more experimental groups). Kaplan-Meier estimates
and the log-rank test were used to analyze statistical differences in progres-
sion-free and overall survival between melanoma patients treated with anti-
PD-1 antibody therapy, whose pre-treatment tumor biopsies showed low
versus high melanoma cell expression of p-S6. Differences in p-S6 expression
in patient-matched tumor biospecimens obtained before and after PD-1 ther-
apy were statistically compared using the paired Student’s t test. Data were
tested for normal distribution using the D’Agostino and Pearson omnibus
normality test. A two-sided value of p < 0.05 was considered statistically
significant.
See also the Supplemental Experimental Procedures.
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